|
Adverse effects in dental pain |
|||||||
| Adverse effects with active |
Adverse effects with placebo |
||||||
|
|
|||||||
| Number of trials |
Drug and dose |
Number |
Percent |
Number |
Percent |
Relative risk (95% CI) |
NNH/NNTp (95% CI) |
|
|
|||||||
| Any adverse event |
|||||||
| 13 |
Rofecoxib 50 mg |
459/1330 |
35 |
231/570 |
41 |
0.9 (0.8 to 1.0) |
nc |
| 6 |
Ibuprofen 400 mg |
102/303 |
34 |
122/298 |
41 |
0.8 (0.7 to 1.0) |
nc |
|
|
|||||||
| 1 |
Diclofenac 50 mg* |
72/121 |
60 |
31/63 |
41 |
1.2 (0.9 to 1.6) |
nc |
| 6 |
Ibuprofen 400 mg |
102/303 |
34 |
122/298 |
41 |
0.8 (0.7 to 1.0) |
nc |
| 2 |
Naproxen 550 mg |
27/88 |
31 |
25/87 |
29 |
1.1 (0.7 to 1.7) |
nc |
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
116/180 |
64 |
29/61 |
48 |
1.4 (1.02 to 1.8) |
5.9 (3.2 to 39) |
| 2 |
paracetamol 600 mg + codeine 60 mg |
146/360 |
41 |
24/61 |
39 |
1.0 (0.7 to 1.4) |
nc |
|
|
|||||||
| Post-extraction alveolitis |
|||||||
| 13 |
Rofecoxib 50 mg |
179/1330 |
13 |
52/570 |
9 |
1.5 (1.1 to 2.1) |
24 (14 to 80) |
| 6 |
Ibuprofen 400 mg |
23/304 |
8 |
31/298 |
10 |
0.7 (0.4 to 1.2) |
nc |
|
|
|||||||
| 1 |
Diclofenac 50 mg* |
9/180 |
5 |
3/63 |
5 |
1.0 (0.3 to 3.8) |
nc |
| 6 |
Ibuprofen 400 mg |
23/304 |
8 |
31/298 |
10 |
0.7 (0.4 to 1.2) |
nc |
| 2 |
Naproxen 550 mg |
13/88 |
15 |
8/87 |
10 |
1.6 (0.7 to 3.4) |
nc |
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
20/180 |
11 |
7/61 |
11 |
0.9 (0.4 to 2.2) |
nc |
| 2 |
Paracetamol 600 mg + codeine 60 mg |
27/360 |
8 |
3/61 |
6 |
1.3 (0.5 to 3.9) |
nc |
|
|
|||||||
| Dizziness |
|||||||
| 13 |
Rofecoxib 50 mg |
30/1330 |
2 |
25/570 |
5 |
0.5 (0.3 to 0.9) |
43 (24 to 253) |
| 6 |
Ibuprofen 400 mg |
7/304 |
3 |
13/298 |
5 |
0.6 (0.3 to 1.4) |
nc |
|
|
|||||||
| 1 |
Diclofenac 50 mg* |
9/180 |
8 |
5/63 |
8 |
0.6 (0.2 to 1.8) |
nc |
| 6 |
Ibuprofen 400 mg |
7/304 |
3 |
13/298 |
5 |
0.6 (0.3 to 1.4) |
nc |
| 2 |
Naproxen 550 mg |
1/88 |
2 |
1/87 |
1 |
0.9 (0.2 to 9.3) |
nc |
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
44/180 |
24 |
6/61 |
10 |
2.5 (1.1 to 5.6) |
6.9 (4.1 to 21) |
| 2 |
Paracetamol 600 mg + codeine 60 mg |
19/360 |
1 |
1/61 |
2 |
3.3 (0.5 to 24) |
nc |
|
|
|||||||
| Drowsiness |
|||||||
| 13 |
Rofecoxib 50 mg |
8/1330 |
0.6 |
1/570 |
0.6 |
0.9 (0.3 to 3.1) |
nc |
| 6 |
Ibuprofen 400 mg |
1/304 |
0.7 |
0/298 |
0.5 |
1.3 (0.2 to 11) |
nc |
|
|
|||||||
| 1 |
Diclofenac 50 mg* |
5/180 |
3 |
0/63 |
0 |
3.5 (0.2 to 64) |
nc |
| 6 |
Ibuprofen 400 mg |
1/304 |
0.7 |
0/298 |
0.5 |
1.3 (0.2 to 11) |
nc |
| 2 |
Naproxen 550 mg |
0/88 |
0 |
0/87 |
0 |
0.9 (0.0 to 16) |
nc |
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
6/180 |
4 |
1/61 |
2 |
2.2 (0.3 to 18) |
nc |
| 2 |
Paracetamol 600 mg + codeine 60 mg |
7/360 |
2 |
1/61 |
2 |
1.2 (0.2 to 9.2) |
nc |
|
|
|||||||
| Nausea |
|||||||
| 13 |
Rofecoxib 50 mg |
112/1330 |
8 |
80/570 |
14 |
0.6 (0.5 to 0.8) |
18 (11 to 41) |
| 6 |
Ibuprofen 400 mg |
38/304 |
12 |
51/298 |
17 |
0.7 (0.5 to 1.08) |
nc |
|
|
|||||||
| 1 |
Diclofenac 50 mg* |
21/180 |
12 |
10/63 |
16 |
0.7 (0.4 to 1.5) |
nc |
| 6 |
Ibuprofen 400 mg |
38/304 |
12 |
51/298 |
17 |
0.7 (0.5 to 1.08) |
nc |
| 2 |
Naproxen 550 mg |
4/88 |
5 |
3/87 |
3 |
1.3 (0.3 to 5.7) |
nc |
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
61/180 |
34 |
10/61 |
17 |
2.0 (1.1 to 3.5) |
6.0 (3.5 to 19) |
| 2 |
Paracetamol 600 mg + codeine 60 mg |
70/360 |
19 |
6/61 |
10 |
2.0 (0.9 to 4.4) |
10 (5.5 to 92) |
|
|
|||||||
| Vomiting |
|||||||
| 13 |
Rofecoxib 50 mg |
51/1330 |
4 |
51/570 |
9 |
0.4 (0.3 to 0.6) |
19 (13 to 38) |
| 6 |
Ibuprofen 400 mg |
25/304 |
8 |
36/298 |
12 |
0.7 (0.4 to 1.1) |
nc |
|
|
|||||||
| 1 |
Diclofenac 50 mg* |
6/180 |
3 |
7/63 |
11 |
0.3 (0.1 to 1.0) |
nc |
| 2 |
Naproxen 550 mg |
1/88 |
2 |
1/87 |
2 |
0.9 (0.1 to 9.3) |
nc |
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
35/180 |
19 |
3/61 |
6 |
3.4 (1.2 to 9.8) |
7.2 (4.6 to 18) |
| 2 |
Paracetamol 600 mg + codeine 60 mg |
58/360 |
16 |
4/61 |
7 |
2.46 (0.9 to 6.5) |
10 (5.9 to 44) |
|
*NB: Diclofenac was taken every eight hours during the study. Naproxen was given as the sodium salt Bold type: NNTp to prevent one event (significantly fewer events occurred with rofecoxib 50 mg compared with placebo | |||||||
Edwards et al. BMC Anesthesiology 2004 4:3 doi:10.1186/1471-2253-4-3 |
|||||||